RU2013133813A - Средства для выведения биомолекул из кровотока - Google Patents
Средства для выведения биомолекул из кровотока Download PDFInfo
- Publication number
- RU2013133813A RU2013133813A RU2013133813/15A RU2013133813A RU2013133813A RU 2013133813 A RU2013133813 A RU 2013133813A RU 2013133813/15 A RU2013133813/15 A RU 2013133813/15A RU 2013133813 A RU2013133813 A RU 2013133813A RU 2013133813 A RU2013133813 A RU 2013133813A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- aryl
- group
- independently
- agent
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims abstract 77
- 125000003118 aryl group Chemical group 0.000 claims abstract 73
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 29
- 125000001424 substituent group Chemical group 0.000 claims abstract 10
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 239000008280 blood Substances 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 125000002897 diene group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 150000002402 hexoses Chemical class 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical class N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 150000001721 carbon Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- -1 4-pyrimidyl Chemical group 0.000 claims 3
- 150000001993 dienes Chemical class 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241001168730 Simo Species 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196092.0 | 2010-12-21 | ||
| EP10196092 | 2010-12-21 | ||
| PCT/IB2011/055730 WO2012085789A1 (en) | 2010-12-21 | 2011-12-16 | Agents for clearing biomolecules from circulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013133813A true RU2013133813A (ru) | 2015-01-27 |
Family
ID=43530614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013133813/15A RU2013133813A (ru) | 2010-12-21 | 2011-12-16 | Средства для выведения биомолекул из кровотока |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9427482B2 (enExample) |
| EP (1) | EP2654796A1 (enExample) |
| JP (1) | JP5992435B2 (enExample) |
| CN (1) | CN103328008B (enExample) |
| RU (1) | RU2013133813A (enExample) |
| WO (1) | WO2012085789A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6215194B2 (ja) * | 2011-05-16 | 2017-10-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 生体直交型薬物活性化 |
| WO2014081299A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| WO2014081301A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| WO2014081300A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| DK2922574T3 (da) * | 2012-11-22 | 2023-08-21 | Tagworks Pharmaceuticals B V | Kemisk spaltbar gruppe |
| ES2966631T3 (es) | 2013-06-19 | 2024-04-23 | Univ California | Estructuras químicas para el suministro localizado de agentes terapéuticos |
| JP6625550B2 (ja) | 2014-03-14 | 2019-12-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｃｏ複合体および治療薬の送達のための方法 |
| WO2016025480A1 (en) | 2014-08-11 | 2016-02-18 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| WO2017044983A1 (en) | 2015-09-10 | 2017-03-16 | Shasqi, Inc. | Bioorthogonal compositions |
| US11617799B2 (en) * | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US10222346B2 (en) * | 2017-01-09 | 2019-03-05 | National Research Council Of Canada | Decomposable S-tetrazine based polymers for single walled carbon nanotube applications |
| ES2875562T3 (es) | 2017-01-11 | 2021-11-10 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| ES2983582T3 (es) | 2017-04-07 | 2024-10-23 | Tambo Inc | Composiciones bioortogonales |
| AU2018297272B2 (en) | 2017-07-06 | 2022-10-27 | Memorial Sloan Kettering Cancer Center | DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy |
| US11559494B2 (en) | 2017-07-14 | 2023-01-24 | The Penn State Research Foundation | Compositions and methods for targeted delivery of therapeutic and/or diagnostic species |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| CN112088169A (zh) | 2018-03-12 | 2020-12-15 | 纪念斯隆凯特琳癌症中心 | 双特异性结合剂及其用途 |
| AU2019344897B2 (en) | 2018-09-18 | 2024-01-18 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors |
| IL289095A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Activating components to cleave labels from biomolecules in vivo |
| EP4382129A3 (en) | 2019-06-17 | 2024-07-03 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| KR20250141267A (ko) * | 2023-02-15 | 2025-09-26 | 태그웍스 파마슈티컬스 비.브이. | 개선된 특성을 가지는 테트라진 |
| WO2025166289A1 (en) * | 2024-01-31 | 2025-08-07 | Oregon State University | Tunable tetrazine amino acids for encodable protein labeling |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075010A (en) | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| US5616690A (en) | 1992-06-09 | 1997-04-01 | Neorx Corporation | Hexose derivatized human serum albumin clearing agents |
| US5624896A (en) | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
| US20030129191A1 (en) | 1992-12-23 | 2003-07-10 | Neorx Corporation | Pretargeting methods and compounds |
| WO1995015978A1 (en) | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| DE69433343D1 (de) | 1993-12-07 | 2003-12-24 | Neorx Corp | Pretargeting verfahren und mitteln |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
| US5886143A (en) | 1994-12-07 | 1999-03-23 | Neorx Corporation | Hepatic-directed compounds and reagents for preparation thereof |
| WO1996040245A1 (en) | 1995-06-07 | 1996-12-19 | Immunomedics, Inc. | Improved delivery of diagnostic and therapeutic agents to a target site |
| US7052872B1 (en) | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
| EP1799273A2 (en) | 2004-10-07 | 2007-06-27 | Koninklijke Philips Electronics N.V. | Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy |
| CN101511389A (zh) | 2005-10-04 | 2009-08-19 | 皇家飞利浦电子股份有限公司 | 使用[3+2]叠氮化物-炔环加成的靶向成像和/或治疗 |
| EP2361098B1 (en) | 2008-10-31 | 2019-08-28 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
| EP2419141A1 (en) * | 2009-04-16 | 2012-02-22 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| US20120034161A1 (en) | 2009-04-16 | 2012-02-09 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| WO2012082773A1 (en) | 2010-12-13 | 2012-06-21 | Biomimetic Therapeutics, Inc. | Compositions and methods for spine fusion procedures |
-
2011
- 2011-12-16 RU RU2013133813/15A patent/RU2013133813A/ru not_active Application Discontinuation
- 2011-12-16 US US13/994,783 patent/US9427482B2/en active Active
- 2011-12-16 EP EP11807788.2A patent/EP2654796A1/en not_active Withdrawn
- 2011-12-16 WO PCT/IB2011/055730 patent/WO2012085789A1/en not_active Ceased
- 2011-12-16 JP JP2013545584A patent/JP5992435B2/ja active Active
- 2011-12-16 CN CN201180061889.9A patent/CN103328008B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130272959A1 (en) | 2013-10-17 |
| CN103328008A (zh) | 2013-09-25 |
| WO2012085789A1 (en) | 2012-06-28 |
| US9427482B2 (en) | 2016-08-30 |
| JP5992435B2 (ja) | 2016-09-14 |
| CN103328008B (zh) | 2016-02-24 |
| JP2014500307A (ja) | 2014-01-09 |
| EP2654796A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013133813A (ru) | Средства для выведения биомолекул из кровотока | |
| RU2013121799A (ru) | Набор для претаргетинга, способ и агенты, применяемые в нем | |
| RU2005138719A (ru) | Новые бисамидатные фосфонатные пролекарства | |
| JP2016193934A5 (enExample) | ||
| JP2011516428A5 (enExample) | ||
| RU96107113A (ru) | C-22 циклические стабилизированные производные рапамицина | |
| ES2992544T3 (es) | Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos | |
| MX347544B (es) | Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo. | |
| RU2011107752A (ru) | Агенты, связывающиеся с psma, и их применение | |
| JP2018520195A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2015106915A (ru) | МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ | |
| RU2014128479A (ru) | Комбинированная терапия для стабильного и долговременного приживления трансплантата | |
| CA2455559A1 (en) | Methods to mobilize progenitor/stem cells | |
| JP2009504772A5 (enExample) | ||
| AR010743A1 (es) | Compuestos de pirazol, utiles como inhibidores de la liberacion de acidos grasos mediada por la fosfolipasa a2 secretora no pancreatica humana.procedimientos para preparar dichos compuestos y composiciones farmaceuticas formuladas con dichos compuestos | |
| EA018983B1 (ru) | Способ усиления миграции гемопоэтических стволовых клеток, способ получения популяции указанных клеток и способы лечения с их использованием | |
| ES2913073T3 (es) | Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| RU2014150569A (ru) | Конъюгат фотосенсибилизатора и хитозана и его применение | |
| JP2017537886A5 (enExample) | ||
| RU2019128063A (ru) | Углеводородсульфонилзамещенные пиридины и их применение при лечении рака | |
| JP2012523432A5 (enExample) | ||
| CN120699073A (zh) | 烟酰胺单核苷酸衍生物及其在治疗和预防红细胞病症中的用途 | |
| ES2984026T3 (es) | Antagonistas del receptor de tromboxano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160428 |